Your browser doesn't support javascript.

Biblioteca Virtual em Saúde

Brasil

Home > Pesquisa > ()
Imprimir Exportar

Formato de exportação:

Exportar

Email
Adicionar mais destinatários
| |

Managing adverse effects by dose reduction during routine treatment of locally advanced basal cell carcinoma with the hedgehog inhibitor vismodegib: a single center experience.

Woltsche, Nora; Pichler, Nadja; Wolf, Ingrid; Di Meo, Nicola; Zalaudek, Iris.
Artigo em Inglês | MEDLINE | ID: mdl-30472793
Locally advanced basal cell carcinoma (laBCC) represents an uncommon, difficult to treat form of skin cancer (1,2). The approval of hedgehog inhibitor (HHI) vismodegib in 2012 opened a novel therapeutic option (2-10). "Drug holidays" have been proposed to increase patients' compliance and adherence which is poor due to the high frequency of adverse effects (AE's) of HHI (3-5), however, up to date, the effect of dose reduction during HHI treatment has not been reported. Herein we report the data of a single center's experience in dose adjustment in 13 patients with laBCC treated with vismodegib. This article is protected by copyright. All rights reserved.
Selo DaSilva